Cited 0 time in
Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김경아 | - |
| dc.date.accessioned | 2023-05-11T11:41:35Z | - |
| dc.date.available | 2023-05-11T11:41:35Z | - |
| dc.date.issued | 2021-08-27 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/12070 | - |
| dc.title | Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes | - |
| dc.type | Conference | - |
| dc.citation.conferenceName | ESC congress 2021 | - |
| dc.citation.conferencePlace | 유럽 | - |
| dc.citation.conferencePlace | virtual | - |
| dc.citation.conferenceDate | 2021-08-27 ~ 2021-08-30 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
